Theralase Technologies Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Theralase Technologies Inc. (TSXV: TLT; OTCQB: TLTFF), a clinical-stage pharmaceutical company founded in 1994 and headquartered at 41 Hollinger Road, Toronto, Ontario, Canada, develops and commercializes light-activated photodynamic compounds (PDCs) and proprietary medical laser systems for bio-stimulative and bio-destructive applications targeting cancer, bacteria, viruses, and chronic pain conditions; operations span two divisions, with the Drug Division focused on patented and patent-pending PDCs including lead anti-cancer candidate TLD-1433 for non-muscle invasive bladder cancer (NMIBC), Rutherrin for radiation-activated cancer therapies in glioblastoma multiforme, non-small cell lung cancer, pancreatic and colorectal cancers, and Ruvidar for antiviral applications such as herpes simplex virus type 1, activated by custom laser systems like the TLC-3200 study device; and the Device Division designing, manufacturing and marketing superpulsed diode laser technology cleared by Health Canada and the U.S. FDA, including the TLC-2100 and SMART laser systems for cool laser therapy (CLT) to eliminate chronic knee pain, reduce inflammation, accelerate tissue healing in nerve, muscle and joint conditions, and enhance standard cancer treatments. The company primarily serves healthcare practitioners, clinics and research institutions in Canada, the United States and select international markets. Recent developments include preclinical data in November 2025 demonstrating Rutherrin's 100-fold greater cancer cell kill versus radiation alone across multiple models with plans for GLP toxicology in 2026; peer-reviewed publication in September 2025 validating Ruvidar's superiority against HSV-1; closure of non-brokered private placements raising approximately CAD 1.35 million across two tranches in June and July 2025; extensions of warrant expiry dates totaling over 6.6 million warrants to 2028 in June through August 2025 to support ongoing funding needs; advancement of Phase II NMIBC study with interim data review via conference call in November 2025 showing prior 33% complete response rate at 90 days; and a research collaboration with the University of Windsor on CLT for Parkinson's disease as noted in 2024 financials released in 2025.
Company News
Theralase(R) Releases Q2 2026 Financial Statements
Theralase(R) Closes C$3.6 Million Brokered Financing
Theralase(R) Announces $5 Million Brokered LIFE Offering
Theralase(R) Grants Stock Options
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Theralase(R) Lists Warrants on the TSXV
Theralase(R) Releases Q1 2026 Financial Statements
Theralase(R) Closes C$4.8 Million Offering
Theralase Technologies Inc. (TLT:CA) Q4 2025 Earnings Call Transcript
Theralase(R) Announces $4 Million Brokered LIFE Offering
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Theralase(R) Closes $CAN 2.66 Million Financing
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting